title: Everolimus in ileum neuroendocrine tumours - Authors' reply.
authors.affiliation: University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jyao@mdanderson.org.
authors.forename: James C
authors.initials: JC
authors.lastname: Yao
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Voi
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Rouyrre
authors.affiliation: Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
authors.forename: Simron
authors.initials: S
authors.lastname: Singh
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus